3-methyl-4-oxo-imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylic acid N-hydroxysuccinimide ester | 473988-39-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑四嗪类
• 英文名称: 3-methyl-4-oxo-imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylic acid N-hydroxysuccinimide ester
• 英文别名: temozolomide acid N-hydroxysuccinimide ester；(2,5-Dioxopyrrolidin-1-yl) 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate
• CAS: 473988-39-5
• 化学式: C₁₀H₈N₆O₅
• 分子量: 292.211
• InChiKey: HXYSAWUJUSPATJ-UHFFFAOYSA-N

物化性质

• 沸点：
  521.0±60.0 °C(Predicted)
• 密度：
  1.95±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  127
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  氨苄西林 、 3-methyl-4-oxo-imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylic acid N-hydroxysuccinimide ester 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以37%的产率得到α-[(3-methyl-4-oxo-imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxyl)aminobenzyl]penicillin
  参考文献：
  名称：

  Synthesis and antibacterial activity of dual-action agents of a β-lactam antibiotic with cytotoxic agent mitozolomide or temozolomide

  摘要：

  Dual-action agents 5a-f and 12a-f. a beta-lactam antibiotic combined with a cytotoxic agent. mitozolomide (Meto) or temozolomide (Temo). were synthesised. The antibacterial activity (MICs) of the dual-action agents has been determined against a panel of bacteria including several beta-lactamase producing strains. The tests showed 5a-f active against the non-p-lactamase producing methicillin sensitive Staphylococcus aureus (MSSA) strains. however, little synergistic effect between the P-lactam and the cytotoxic agent was observed. 12a-f demonstrated some synergistic effect against bacteria. 12a. in particular. is active against ampicillin resistant (beta-lactamase-producing) strains of Serratia marcescens. (C) 2002 Published by editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(01)01331-9
• 作为产物：
  描述：

  替莫唑胺 在 硫酸 、 N,N'-二环己基碳二亚胺 、 sodium nitrite 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 3-methyl-4-oxo-imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxylic acid N-hydroxysuccinimide ester
  参考文献：
  名称：

  Synthesis and antibacterial activity of dual-action agents of a β-lactam antibiotic with cytotoxic agent mitozolomide or temozolomide

  摘要：

  Dual-action agents 5a-f and 12a-f. a beta-lactam antibiotic combined with a cytotoxic agent. mitozolomide (Meto) or temozolomide (Temo). were synthesised. The antibacterial activity (MICs) of the dual-action agents has been determined against a panel of bacteria including several beta-lactamase producing strains. The tests showed 5a-f active against the non-p-lactamase producing methicillin sensitive Staphylococcus aureus (MSSA) strains. however, little synergistic effect between the P-lactam and the cytotoxic agent was observed. 12a-f demonstrated some synergistic effect against bacteria. 12a. in particular. is active against ampicillin resistant (beta-lactamase-producing) strains of Serratia marcescens. (C) 2002 Published by editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(01)01331-9

文献信息

• PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN-BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING
  申请人：Vision Global Holdings Ltd.

  公开号：US20140335018A1

  公开（公告）日：2014-11-13

  The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

  本发明提供了一种含有基于血红蛋白的治疗药物的药物组合物，用于治疗癌症。血红蛋白部分可以靶向癌细胞，治疗部分（即活性剂/治疗药物）可以高效地杀死癌细胞。本发明中使用的基于血红蛋白的治疗药物可用于治疗各种癌症，如胰腺癌、白血病、头颈癌、结直肠癌、肺癌、乳腺癌、肝癌、鼻咽癌、食管癌、前列腺癌、胃癌和脑癌。该组合物可单独使用或与其他治疗剂（如化疗剂）结合使用，对癌症治疗产生协同作用，抑制转移和/或减少复发。目前申请的基于血红蛋白的5FU-双染料共轭物和/或基于血红蛋白的5FU-单染料共轭物也可用于活细胞成像和诊断成像。
• [EN] ARYL-FUSED ISOSELENAZOLE COMPOUND CONTAINING TETRAZINE SUBSTITUENT, SYNTHESIS METHOD THEREFOR, AND USE THEREOF<br/>[FR] COMPOSÉ D'ISOSÉLÉNAZOLE À FUSION ARYLE CONTENANT UN SUBSTITUANT DE TÉTRAZINE, SON PROCÉDÉ DE SYNTHÈSE ET SON UTILISATION<br/>[ZH] 含四嗪取代基的芳并异硒唑类化合物及其合成方法和应用
  申请人：KEAISE MEDICINE WUHAN CORP

  公开号：WO2021208865A1

  公开（公告）日：2021-10-21

  本发明提供了式(I)和式(II)所示的含四嗪取代基的芳并异硒唑类化合物及其制备方法和应用。本发明的化合物具有TrxR抑制活性，具备靶向TrxR靶点特点，因此其对于肿瘤，特别是脑胶质瘤具有良好的抗肿瘤功效。本发明的化合物作为药物在体内和体外都能很好的抑制肿瘤细胞的生长。